Skip to main content

Table 3 Survival by subgroup in ITT population

From: Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study

Subgroup

Median OS (95%CI) months

1-year survival rate

%

no./total no.

Overall

11.0 (6.9 – 19.8)

45.0

13/29

Gender

   

Female

13.9 (6.9 – 19.8)

53.3

8/15

Male

8.7 (4.7 – 14.6)

36.4

5/14

Performance status

   

ECOG 0

10.8 (6.9 – 19.8)

43.8

7/16

ECOG 1

11.0 (5.1 – 19.8)

46.8

6/13

Metastasis stage

   

M1a

14.6 (10.3 – 14.6)

66.7

2/3

M1b

19.8 (1.2 – 19.8)

75.0

3/4

M1c

8.8 (6.3 – 14.3)

36.4

8/22

Age

   

≤60 years

9.8 (6.4 – 14.6)

30.0

3/10

>60 years

13.9 (6.3 – 19.8)

53.1

10/19

Pre-treatment

   

1

11.3 (6.9 - 13.9)

46.9

7/15

≥2

10.0 (5.1 – 14.6)

42.9

6/14

Patients

   

Non-progressive

14.2 (11.3 – 19.8)

72.7

8/11

Progressive

8.4 (5.1 – 11.0)

28.1

5/18

  1. OS = overall survival, ITT = intention to treat, CI confidence interval.
Back to article page